EZH2 and follicular lymphoma: Another inhibitor of EZH2, Tazemetostat (TAZVERIK, Epizyme, Inc.)was approved by US- FDA in June 2020 for treating adult patients with relapsed or follicular lymphoma with EZH2 positive mutations.